Skip to main content
Skip to main content
Home
Company
About Us
Executive Team
Board of Directors
Scientific & Clinical Advisors
Partners
Technology
Itolizumab
Multi-Cytokine Inhibitor Platform
Publications
Presentations
Clinical
Pipeline
Clinical Studies
Expanded Access Policy
Investors
Investor Overview
Stock Information
Stock Chart
Analyst Coverage
Press Releases
Events & Presentations
Email Alerts & Contacts
SEC Filings
Corporate Governance
Governance Documents
Committee Composition
Investor FAQs
Careers
Contact Us
Search query
Our Company
About Us
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways.
Our Executive Team
We have the privilege to work as a team towards fulfillment of our mission to pioneer new innovations to treat autoimmune and inflammatory diseases and most importantly to make a difference in the lives of patients.
Our Board of Directors
Scientific and Clinical Advisors
Our Partners
As Equillium was founded, the company acquired rights for developing and commercializing itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.
